骨转换标志物I型胶原C末端肽（1CTP）和I型前胶原N末端前肽（P1NP）在前列腺癌骨转移患者中的肿瘤学验证。

Oncological validation of bone turnover markers c-terminal telopeptide of type I collagen (1CTP) and peptides n-terminal propeptide of type I procollagen (P1NP) in patients with prostate cancer and bone metastases.

作者信息

Aufderklamm Stefan, Hennenlotter Jörg, Rausch Steffen, Bock Cornelia, Erne Eva, Schwentner Christian, Stenzl Arnulf

机构信息

Department of Urology, Eberhard-Karls University Tübingen, Tübingen, Germany.

Department of Urology, Diakonieklinikum Stuttgart, Stuttgart, Germany.

出版信息

Transl Androl Urol. 2021 Oct;10(10):4000-4008. doi: 10.21037/tau-20-1120.

DOI:10.21037/tau-20-1120

PMID:34804842

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8575559/

Abstract

BACKGROUND

Bone formation markers c-terminal telopeptide of type I collagen (1CTP) and peptides n-terminal propeptide of type I procollagen (P1NP) were reported to be increased in patients with prostate cancer (PC) and bone metastases. The objective of the presented study was to investigate the utility of serum 1CTP and P1NP values in the diagnosis of bone metastases and in predicting oncological outcome in patients with PC.

METHODS

In total, serum samples of 186 patients were included retrospectively including 53 (28.50%) benign prostatic hyperplasia (BPH) patients and 133 (71.50%) PC-patients. The group of patients with PC consisted of 58 patients with non-metastatic PC (cM0) (43.61%) and 70 (52.63%) patients with bone metastases (cM1b). Serum 1CTP and P1NP were measured by radioimmunoassay (RIA). Results were compared to clinical variables including oncologic follow-up data by univariate and multivariate analyses.

RESULTS

Median 1CTP concentrations were significantly higher in patients with PC compared to the BPH group [5.08 (range, 1.73-158.00) . 4.00 (range, 2.18-34.19) µg/L, P=0.019]. However, no significant difference of P1NP levels could be shown for these groups. With median values of 6.04 (1.73-158.00) and 3.91 µg/L (2.04-34.51) for 1CTP and 48.60 (9.12-1,074.37) and 33.90 (8.72-149.30) for P1NP both markers were altered in cM1b patients compared to cM0 patients (P=0.001 each). Furthermore, cancer-specific survival (CSS) and overall survival (OS) were significantly shorter in cM1b patients with higher 1CTP concentrations (P=0.037 and P=0.019, respectively), whereas no associations of P1NP and outcomes were observed.

CONCLUSIONS

The present study confirms that increased levels of 1CTP and P1NP concentrations are associated with presence of metastatic disease in the bone. Moreover, these markers are able to predict clinical course in PC patients with bone metastases. The potential use of these markers for treatment selection in advanced PC remains to be determined.

摘要

背景

据报道，前列腺癌（PC）和骨转移患者的骨形成标志物I型胶原C末端肽（1CTP）和I型前胶原N末端肽（P1NP）会升高。本研究的目的是探讨血清1CTP和P1NP值在骨转移诊断及预测PC患者肿瘤学结局中的作用。

方法

回顾性纳入186例患者的血清样本，其中包括53例（28.50%）良性前列腺增生（BPH）患者和133例（71.50%）PC患者。PC患者组包括58例非转移性PC患者（cM0）（43.61%）和70例（52.63%）骨转移患者（cM1b）。采用放射免疫分析法（RIA）检测血清1CTP和P1NP。通过单因素和多因素分析将结果与包括肿瘤学随访数据在内的临床变量进行比较。

结果

与BPH组相比，PC患者的1CTP浓度中位数显著更高[5.08（范围，1.73 - 158.00）. 4.00（范围，2.18 - 34.19）μg/L，P = 0.019]。然而，这些组的P1NP水平未显示出显著差异。1CTP在cM1b患者中的中位数为6.04（1.73 - 158.00）μg/L，在cM0患者中为3.91μg/L（2.04 - 34.51）μg/L；P1NP在cM1b患者中的中位数为48.60（9.12 - 1,074.37）μg/L，在cM0患者中为33.90（8.72 - 149.30）μg/L，与cM0患者相比，cM1b患者的这两种标志物均有改变（均P = 0.001）。此外，1CTP浓度较高的cM1b患者的癌症特异性生存（CSS）和总生存（OS）显著缩短（分别为P = 0.037和P = 0.019），而未观察到P1NP与结局之间的关联。